View Item 

Show simple item record

Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18
dc.contributor.authorVolkmann, Elizabeth R.
dc.contributor.authorTashkin, Donald P.
dc.contributor.authorKuwana, Masataka
dc.contributor.authorLi, Ning
dc.contributor.authorRoth, Michael D.
dc.contributor.authorCharles, Julio
dc.contributor.authorHant, Faye N.
dc.contributor.authorBogatkevich, Galina S.
dc.contributor.authorAkter, Tanjina
dc.contributor.authorKim, Grace
dc.contributor.authorGoldin, Jonathan
dc.contributor.authorKhanna, Dinesh
dc.contributor.authorClements, Philip J.
dc.contributor.authorFurst, Daniel E.
dc.contributor.authorElashoff, Robert M.
dc.contributor.authorSilver, Richard M.
dc.contributor.authorAssassi, Shervin
dc.date.accessioned2020-01-13T15:14:03Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-01-13T15:14:03Z
dc.date.issued2019-12
dc.identifier.citationVolkmann, Elizabeth R.; Tashkin, Donald P.; Kuwana, Masataka; Li, Ning; Roth, Michael D.; Charles, Julio; Hant, Faye N.; Bogatkevich, Galina S.; Akter, Tanjina; Kim, Grace; Goldin, Jonathan; Khanna, Dinesh; Clements, Philip J.; Furst, Daniel E.; Elashoff, Robert M.; Silver, Richard M.; Assassi, Shervin (2019). "Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18." Arthritis & Rheumatology 71(12): 2059-2067.
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205
dc.identifier.urihttps://hdl.handle.net/2027.42/152958
dc.publisherEuropean Respiratory Society Journals Ltd
dc.publisherWiley Periodicals, Inc.
dc.titleProgression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/152958/1/art41020.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/152958/2/art41020_am.pdf
dc.identifier.doi10.1002/art.41020
dc.identifier.sourceArthritis & Rheumatology
dc.identifier.citedreferenceBenyamine A, Heim X, Resseguier N, Bertin D, Gomez C, Ebbo M, et al. Elevated serum Krebs von den Lungen‐6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease. Rheumatol Int 2018; 38: 813 – 9.
dc.identifier.citedreferenceRoth MD, Tseng CH, Clements PJ, Furst DE, Tashkin DP, Goldin JG, et al, for the Scleroderma Lung Study Research Group. Predicting treatment outcomes and responder subsets in scleroderma‐related interstitial lung disease. Arthritis Rheum 2011; 63: 2797 – 808.
dc.identifier.citedreferenceVolkmann ER, Tashkin DP, Sim M, Kim GH, Goldin J, Clements PJ. Determining progression of scleroderma‐related interstitial lung disease. J Scleroderma Relat Disord 2018; 4: 62 – 70.
dc.identifier.citedreferenceNihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al. Prediction of pulmonary complications and long‐term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66: 1625 – 35.
dc.identifier.citedreferenceKhanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study placebo group. Arthritis Rheum 2011; 63: 3078 – 85.
dc.identifier.citedreferenceMoore OA, Goh N, Corte T, Rouse H, Hennessey O, Thakkar V, et al. Extent of disease on high‐resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis‐related interstitial lung disease. Rheumatology (Oxford) 2013; 52: 155 – 60.
dc.identifier.citedreferenceAssassi S, Sharif R, Lasky RE, McNearney TA, Estrada‐Y‐Martin RM, Draiger H, et al, and the GENISOS Study Group. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010; 12: R166.
dc.identifier.citedreferenceDe Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013; 40: 435 – 46.
dc.identifier.citedreferenceLiu X, Mayes MD, Pedroza C, Draeger HT, Gonzalez EB, Harper BE, et al. Does C‐reactive protein predict the long‐term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res (Hoboken) 2013; 65: 1375 – 80.
dc.identifier.citedreferenceWu M, Pedroza C, Salazar G, Zhou X, Reveille JD, Mayes MD, et al. Plasma MCP‐1 and IL‐10 levels predict long‐term progression of interstitial lung disease in patients with early systemic sclerosis [abstract). Arthritis Rheum 2013; 65 Suppl 10: S742.
dc.identifier.citedreferenceSchupp J, Becker M, Günther J, Müller‐Quernheim J, Riemekasten G, Prasse A. Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis [letter]. Eur Respir J 2014; 43: 1530 – 2.
dc.identifier.citedreferenceTiev KP, Hua‐Huy T, Kettaneh A, Gain M, Duong‐Quy S, Tolédano C, et al. Serum CC chemokine ligand‐18 predicts lung disease worsening in systemic sclerosis. Eur Respir J 2011; 38: 1355 – 60.
dc.identifier.citedreferenceVan Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, et al. Proteome‐wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014; 370: 433 – 43.
dc.identifier.citedreferenceKuwana M, Shirai Y, Takeuchi T. Elevated serum Krebs von den Lungen‐6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J Rheumatol 2016; 43: 1825 – 31.
dc.identifier.citedreferenceSalazar GA, Kuwana M, Wu M, Estrada‐Y‐Martin RM, Ying J, Charles J, et al. KL‐6 but not CCL18 is a predictor of early progression of systemic sclerosis‐related interstitial lung disease. J Rheumatol 2018; 45: 1153 – 8.
dc.identifier.citedreferenceNukiwa T. The role of biomarkers in management of interstitial lung disease: implications of biomarkers derived from type II pneumocytes. In: du Bois RM, Richeldi L, editors. Interstitial lung diseases. European Respiratory Society Monographs. Sheffield (UK): European Respiratory Society Journals Ltd; 2009. p. 47 – 66.
dc.identifier.citedreferenceByrne AJ, Maher TM, Lloyd CM. Pulmonary macrophages: a new therapeutic pathway in fibrosing lung disease? Trends Mol Med 2016; 22: 303 – 16.
dc.identifier.citedreferenceHant FN, Ludwicka‐Bradley A, Wang HJ, Li N, Elashoff R, Tashkin DP, et al, for the Scleroderma Lung Study Research Group. Surfactant protein D and KL‐6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009; 36: 773 – 80.
dc.identifier.citedreferenceKumánovics G, Görbe E, Minier T, Simon D, Berki T, Czirják L. Follow‐up of serum KL‐6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis. Clin Exp Rheumatol 2014; 32 Suppl 86: S138 – 44.
dc.identifier.citedreferenceHesselstrand R, Wildt M, Bozovic G, Andersson‐Sjöland A, Andréasson K, Scheja A, et al. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis. Respir Med 2013; 107: 1079 – 86.
dc.identifier.citedreferenceLee JS, Lee EY, Ha YJ, Kang EH, Lee YJ, Song YW. Serum KL‐6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther 2019; 21: 58.
dc.identifier.citedreferenceElhai M, Hoffmann‐Vold AM, Avouac J, Pezet S, Cauvet A, Leblond A, et al. Performance of candidate serum biomarkers for systemic sclerosis–associated interstitial lung disease. Arthritis Rheumatol 2019; 71: 972 – 82.
dc.identifier.citedreferenceSumida H, Asano Y, Tamaki Z, Aozasa N, Taniguchi T, Toyama T, et al. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: a longitudinal observational study. J Dermatol 2018; 45: 1425 – 33.
dc.identifier.citedreferenceCai M, Bonella F, He X, Sixt SU, Sarria R, Guzman J, et al. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases. Respir Med 2013; 107: 1444 – 52.
dc.identifier.citedreferenceHoffmann‐Vold AM, Tennøe AH, Garen T, Midtvedt Ø, Abraityte A, Aaløkken TM, et al. High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis. Chest 2016; 150: 299 – 306.
dc.identifier.citedreferenceElhaj M, Charles J, Pedroza C, Liu X, Zhou Z, Estrada‐Y‐Martin RM, et al. Can serum surfactant protein D or CC‐chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? J Rheumatol 2013; 40: 1114 – 20.
dc.identifier.citedreferenceSubcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581 – 90.
dc.identifier.citedreferenceMahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751 – 8.
dc.identifier.citedreferenceKim HG, Tashkin DP, Clements PJ, Li G, Brown MS, Elashoff R, et al. A computer‐aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol 2010; 28 Suppl 62: S26 – 35.
dc.identifier.citedreferenceElashoff RM, Li G, and Li N. Joint modeling of longitudinal and time‐to‐event data. 1st ed. Boca Raton (FL): CRC Press; 2016.
dc.identifier.citedreferenceVolkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes‐Elstein L, et al. Short‐term progression of interstitial lung disease in systemic sclerosis predicts long‐term survival in two independent clinical trial cohorts. Ann Rheum Dis 2019; 78: 122 – 30.
dc.identifier.citedreferenceWells AU. Interstitial lung disease in systemic sclerosis. Presse Med 2014; 43: e329 – 43.
dc.identifier.citedreferenceTyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809 – 15.
dc.identifier.citedreferenceSteen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283 – 9.
dc.identifier.citedreferenceTashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al, for the Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655 – 66.
dc.identifier.citedreferenceTashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al, for the Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma‐related interstitial lung disease: Scleroderma Lung Study II (SLS‐II), a double‐blind, parallel group, randomised controlled trial. Lancet Respir Med 2016; 4: 708 – 19.
dc.identifier.citedreferenceVolkmann ER, Chung A, Tashkin DP. Managing systemic sclerosis‐related interstitial lung disease in the modern treatment era. J Scleroderma Relat Disord 2017; 2: 72 – 83.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art41020.pdf
Size:
337.8KB
Format:
PDF
View/Open
Name:
art41020_am.pdf
Size:
318.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.